Centre J.D. MacLean pour maladies tropicales - agrégateur /tropmed/fr/aggregator Centre J.D. MacLean pour maladies tropicales - flux agrégés fr Recent publications from TDC/Clinical Epidemiology authors: Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children https://pubmed.ncbi.nlm.nih.gov/39504434/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20241107015319&v=2.18.0.post9+e462414 CONCLUSIONS: Both LAIV3- and IIV3-elicited HA antibodies are associated with protection against influenza infection in seasons when the vaccine strains match the circulating influenza strain subtypes, supporting the use of HAI as a correlate of protection for both vaccine types in children. Wed, 06 Nov 2024 06:00:00 -0500 Recent publications from TDC/Clinical Epidemiology authors: Host Response Markers of Inflammation and Endothelial Activation Associated with COVID-19 Severity and Mortality: A GeoSentinel Prospective Observational Cohort https://pubmed.ncbi.nlm.nih.gov/39459948/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20241027021134&v=2.18.0.post9+e462414 BACKGROUND: The effect of the COVID-19 pandemic on healthcare systems emphasized the need for rapid and effective triage tools to identify patients at risk of severe or fatal infection. Measuring host response markers of inflammation and endothelial activation at clinical presentation may help to inform appropriate triage and care practices in patients with SARS-CoV-2 infection. Sat, 26 Oct 2024 06:00:00 -0400 Recent publications from TDC/Clinical Epidemiology authors: MicrobiomeNet: exploring microbial associations and metabolic profiles for mechanistic insights https://pubmed.ncbi.nlm.nih.gov/39441071/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20241024005619&v=2.18.0.post9+e462414 The growing volumes of microbiome studies over the past decade have revealed a wide repertoire of microbial associations under diverse conditions. Microbes produce small molecules to interact with each other as well as to modulate their environments. Their metabolic profiles hold the key to understanding these association patterns for translational applications. Based on this concept, we developed MicrobiomeNet, a comprehensive database that integrates microbial associations with their metabolic... Wed, 23 Oct 2024 06:00:00 -0400 Recent publications from TDC/Clinical Epidemiology authors: Analysis of Monkeypox Virus Exposures and Lesions by Anatomic Site https://pubmed.ncbi.nlm.nih.gov/39365696/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20241005014455&v=2.18.0.post9+e462414 We used cross-sectional data from 226 patients with monkeypox virus to investigate the association between anatomic exposure site and lesion development. Penile, anorectal, and oral exposures predicted lesion presence at correlating anatomic sites. Exposure site also predicted the first lesion site of the penis and anus. Fri, 04 Oct 2024 06:00:00 -0400 Recent publications from TDC/Clinical Epidemiology authors: HumanIslets.com: Improving accessibility, integration, and usability of human research islet data https://pubmed.ncbi.nlm.nih.gov/39357523/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20241004020919&v=2.18.0.post9+e462414 HumanIslets.com supports diabetes research by offering easy access to islet phenotyping data, analysis tools, and data download. It includes molecular omics, islet and cellular function assays, tissue processing metadata, and phenotypes from 547 donors. As it expands, the resource aims to improve human islet data quality, usability, and accessibility. Wed, 02 Oct 2024 06:00:00 -0400 Recent publications from TDC/Clinical Epidemiology authors: Green Synthesis and Anti-Inflammatory Activity of Silver Nanoparticles Based on Leaves Extract of <em>Aphania senegalensis</em> https://pubmed.ncbi.nlm.nih.gov/39345265/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20241001003224&v=2.18.0.post9+e462414 This study focuses on the synthesis of silver nanoparticles (AgNPs) using the extract of Aphania senegalensis leaves. The extraction was done using maceration at room temperature in water for 48 h. The synthesized nanoparticles were characterized by IR, XRD, TEM, and SEM. The thermal stability of these nanoparticles was studied by TGA. The zeta potential was used to define the size, charge distribution, and stability of the nanoparticles. Optimization reactions were carried out based on reaction... Mon, 30 Sep 2024 06:00:00 -0400 Recent publications from TDC/Clinical Epidemiology authors: Increasing our knowledge about the epidemiology of <em>Helicobacter pylori</em> in Nunavik's Inuit population (Québec, Canada) using <em>Qanuilirpitaa?</em> 2017 cross-sectional survey https://pubmed.ncbi.nlm.nih.gov/39283038/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20240918023816&v=2.18.0.post9+e462414 Helicobacter pylori is a bacterium that may colonise and proliferate in human stomachs, leading invariably to chronic inflammation and, to a lesser extent, to peptic ulcers and cancer. The main objective of this study is to describe the epidemiology surrounding H. pylori in Nunavik's Inuit population using the 2004 and 2017 Health Surveys. Estimated prevalences were 70.9% for bacterial colonisation using a stool antigens test (SAT), 72.5% for anti-H. pylori antibodies, 12.7% for faecal occult... Mon, 16 Sep 2024 06:00:00 -0400 Recent publications from TDC/Clinical Epidemiology authors: Phytochemical screening, antimicrobial, antioxidant, anticancer activities on cervical cancer cell lines and aero-digestive extract of <em>Moringa oleifera</em> https://pubmed.ncbi.nlm.nih.gov/39257089/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20240912025732&v=2.18.0.post9+e462414 The phytochemical screening showed that the Moringa oleifera (MO) extract contained many compounds such as polyphenols, polyterpenes, sterols, reducing sugars, and hydrolysates tannins. The MICs of MO extract for microbial strains is 0.73 mg/ml for Escherichia coli, Pseudomonas aeruginosa, 7.5 mg/ml for Enterococcus faecalis, Staphylococcus aureus and 0.5 mg/ml for Candida albicans. The MO extract has an IC(50) of 3.403 mg/ml has an antioxidant activity by DPPH radical scavenging. The cytotoxic... Wed, 11 Sep 2024 06:00:00 -0400 Recent publications from TDC/Clinical Epidemiology authors: Helminth-derived metabolites induce tolerogenic functional, metabolic, and transcriptional signatures in dendritic cells that attenuate experimental colitis https://pubmed.ncbi.nlm.nih.gov/39211070/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20240901021118&v=2.18.0.post9+e462414 Inflammatory bowel diseases (IBD) are chronic inflammatory diseases in which abdominal pain, bloody diarrhea, weight loss, and fatigue collectively result in diminished quality of patient life. The disappearance of intestinal helminth infections in Western societies is associated with an increased prevalence of IBD and other immune-mediated inflammatory diseases. Evidence indicates that helminths induce tolerogenic dendritic cells (tolDCs), which promote intestinal tolerance and attenuate... Fri, 30 Aug 2024 06:00:00 -0400 Recent publications from TDC/Clinical Epidemiology authors: Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada https://pubmed.ncbi.nlm.nih.gov/39205198/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zSVwQViw4htk0ptJE-rdb4g98Hn0Vy51ceCnixBnFkL6ILsbf&fc=20201106102241&ff=20240901021118&v=2.18.0.post9+e462414 CONCLUSIONS: Doubling the antibody testing rates, along with increased Ï㽶ÊÓƵ testing and treatment rates, showed promise in meeting the WHO's goals by 2035. Thu, 29 Aug 2024 06:00:00 -0400